|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: B3GNT5 |
Gene summary for B3GNT5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | B3GNT5 | Gene ID | 84002 |
| Gene name | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 | |
| Gene Alias | B3GN-T5 | |
| Cytomap | 3q27.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9BYG0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84002 | B3GNT5 | LZE4T | Human | Esophagus | ESCC | 3.01e-10 | 8.57e-01 | 0.0811 |
| 84002 | B3GNT5 | LZE5T | Human | Esophagus | ESCC | 1.73e-03 | 1.71e-01 | 0.0514 |
| 84002 | B3GNT5 | LZE8T | Human | Esophagus | ESCC | 3.65e-04 | 2.77e-01 | 0.067 |
| 84002 | B3GNT5 | LZE24T | Human | Esophagus | ESCC | 1.46e-09 | 7.53e-01 | 0.0596 |
| 84002 | B3GNT5 | LZE21T | Human | Esophagus | ESCC | 1.39e-04 | 1.06e+00 | 0.0655 |
| 84002 | B3GNT5 | P1T-E | Human | Esophagus | ESCC | 3.45e-04 | 1.20e+00 | 0.0875 |
| 84002 | B3GNT5 | P2T-E | Human | Esophagus | ESCC | 2.22e-43 | 8.35e-01 | 0.1177 |
| 84002 | B3GNT5 | P4T-E | Human | Esophagus | ESCC | 1.08e-25 | 1.21e+00 | 0.1323 |
| 84002 | B3GNT5 | P5T-E | Human | Esophagus | ESCC | 1.19e-19 | 5.61e-01 | 0.1327 |
| 84002 | B3GNT5 | P8T-E | Human | Esophagus | ESCC | 6.93e-27 | 7.25e-01 | 0.0889 |
| 84002 | B3GNT5 | P9T-E | Human | Esophagus | ESCC | 5.91e-23 | 9.59e-01 | 0.1131 |
| 84002 | B3GNT5 | P10T-E | Human | Esophagus | ESCC | 1.70e-17 | 1.48e-01 | 0.116 |
| 84002 | B3GNT5 | P11T-E | Human | Esophagus | ESCC | 1.99e-05 | 1.11e+00 | 0.1426 |
| 84002 | B3GNT5 | P12T-E | Human | Esophagus | ESCC | 3.41e-85 | 2.35e+00 | 0.1122 |
| 84002 | B3GNT5 | P15T-E | Human | Esophagus | ESCC | 7.05e-22 | 7.47e-01 | 0.1149 |
| 84002 | B3GNT5 | P16T-E | Human | Esophagus | ESCC | 3.45e-22 | -7.37e-02 | 0.1153 |
| 84002 | B3GNT5 | P20T-E | Human | Esophagus | ESCC | 1.04e-12 | 5.93e-01 | 0.1124 |
| 84002 | B3GNT5 | P21T-E | Human | Esophagus | ESCC | 4.84e-27 | 6.20e-01 | 0.1617 |
| 84002 | B3GNT5 | P22T-E | Human | Esophagus | ESCC | 1.67e-19 | 4.79e-01 | 0.1236 |
| 84002 | B3GNT5 | P23T-E | Human | Esophagus | ESCC | 7.03e-36 | 1.84e+00 | 0.108 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00066642 | Esophagus | ESCC | glycolipid metabolic process | 63/8552 | 100/18723 | 3.55e-04 | 2.06e-03 | 63 |
| GO:19035092 | Esophagus | ESCC | liposaccharide metabolic process | 63/8552 | 101/18723 | 5.25e-04 | 2.90e-03 | 63 |
| GO:0009247 | Esophagus | ESCC | glycolipid biosynthetic process | 42/8552 | 68/18723 | 5.48e-03 | 2.05e-02 | 42 |
| GO:00064931 | Esophagus | ESCC | protein O-linked glycosylation | 51/8552 | 86/18723 | 7.54e-03 | 2.70e-02 | 51 |
| GO:00066431 | Liver | HCC | membrane lipid metabolic process | 115/7958 | 203/18723 | 3.17e-05 | 3.22e-04 | 115 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0046467 | Liver | HCC | membrane lipid biosynthetic process | 78/7958 | 142/18723 | 1.85e-03 | 9.46e-03 | 78 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:0006664 | Liver | HCC | glycolipid metabolic process | 57/7958 | 100/18723 | 2.40e-03 | 1.17e-02 | 57 |
| GO:1903509 | Liver | HCC | liposaccharide metabolic process | 57/7958 | 101/18723 | 3.25e-03 | 1.49e-02 | 57 |
| GO:00066432 | Oral cavity | OSCC | membrane lipid metabolic process | 111/7305 | 203/18723 | 4.02e-06 | 4.69e-05 | 111 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| B3GNT5 | SNV | Missense_Mutation | c.190N>G | p.Leu64Val | p.L64V | Q9BYG0 | protein_coding | tolerated(0.54) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| B3GNT5 | SNV | Missense_Mutation | novel | c.1021N>T | p.Val341Leu | p.V341L | Q9BYG0 | protein_coding | tolerated(0.68) | benign(0.123) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| B3GNT5 | SNV | Missense_Mutation | c.448G>C | p.Asp150His | p.D150H | Q9BYG0 | protein_coding | tolerated(0.07) | benign(0.231) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| B3GNT5 | SNV | Missense_Mutation | rs750480690 | c.787G>A | p.Asp263Asn | p.D263N | Q9BYG0 | protein_coding | tolerated(0.28) | probably_damaging(0.996) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| B3GNT5 | insertion | Nonsense_Mutation | novel | c.1010_1011insCTTCTTCTCAGTCCAAATAGAAGCAAACCCAGGTTGTATCTG | p.Thr337_Asp338insPhePheSerValGlnIleGluAlaAsnProGlyCysIleTer | p.T337_D338insFFSVQIEANPGCI* | Q9BYG0 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| B3GNT5 | SNV | Missense_Mutation | c.565C>G | p.Leu189Val | p.L189V | Q9BYG0 | protein_coding | tolerated(0.24) | benign(0.019) | TCGA-C5-A2LY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| B3GNT5 | SNV | Missense_Mutation | c.451N>G | p.Gln151Glu | p.Q151E | Q9BYG0 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| B3GNT5 | insertion | Frame_Shift_Ins | novel | c.87_88insT | p.Trp32LeufsTer6 | p.W32Lfs*6 | Q9BYG0 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| B3GNT5 | SNV | Missense_Mutation | c.565N>A | p.Leu189Ile | p.L189I | Q9BYG0 | protein_coding | tolerated(0.2) | benign(0.019) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| B3GNT5 | SNV | Missense_Mutation | novel | c.453N>T | p.Gln151His | p.Q151H | Q9BYG0 | protein_coding | tolerated(0.2) | benign(0.007) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |